Pentavac Stungulyfsstofn og dreifa, dreifa Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

pentavac stungulyfsstofn og dreifa, dreifa

sanofi pasteur* - filamentous haemagglutinin; poliovirus inactivated type 2; poliovirus inactivated type 3; diphtheria toxoid; tetanus toxoid; poliovirus inactivated type 1; pertussis toxoid; haemophilus influenzae type b - stungulyfsstofn og dreifa, dreifa

Supemtek Unia Europejska - islandzki - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - inflúensu, manna - bóluefni - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Typhim Vi Stungulyf, lausn 25 míkróg/0,5 ml Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

typhim vi stungulyf, lausn 25 míkróg/0,5 ml

sanofi pasteur* - salmonella typhi vi antigen - stungulyf, lausn - 25 míkróg/0,5 ml

Repevax Stungulyf, dreifa áfyllt sprauta Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

repevax stungulyf, dreifa áfyllt sprauta

sanofi pasteur* - tetanus toxoid; diphtheria toxoid; pertussis toxoid; filamentous haemagglutinin; pertussis fimbrial agglutinogens (fim) 2 and 3; pertactin; poliovirus (inactivated) type 1 (mahoney strain); poliovirus (inactivated) type 2 (mef-1 strain); poliovirus (inactivated) type 3 (saukett strain) - stungulyf, dreifa - áfyllt sprauta

Insulin lispro Sanofi Unia Europejska - islandzki - EMA (European Medicines Agency)

insulin lispro sanofi

sanofi winthrop industrie - insúlín lispró - sykursýki - lyf notuð við sykursýki - fyrir meðferð fullorðna og börn með sykursýki sem þurfa insúlín til að viðhalda eðlilegt glúkósa homeostasis. insúlín lispró sanofi er einnig ætlað til upphafs stöðugleika sykursýki.

Insulin aspart Sanofi Unia Europejska - islandzki - EMA (European Medicines Agency)

insulin aspart sanofi

sanofi winthrop industrie - insúlín aspart - sykursýki - lyf notuð við sykursýki - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Stamaril Stungulyfsstofn og leysir, dreifa Islandia - islandzki - LYFJASTOFNUN (Icelandic Medicines Agency)

stamaril stungulyfsstofn og leysir, dreifa

sanofi pasteur* - gulusóttarveira 17d-204 stofn (lifandi, veikluð) - stungulyfsstofn og leysir, dreifa

Dengvaxia Unia Europejska - islandzki - EMA (European Medicines Agency)

dengvaxia

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - fjölmörgum - bóluefni - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. notkun dengvaxia ætti að vera í samræmi við opinbera tillögur.

Hexacima Unia Europejska - islandzki - EMA (European Medicines Agency)

hexacima

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) er ætlað fyrir aðal og orku bólusetningu ungbarna og smábörn frá sex vikna gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og innrásar sjúkdóma sem orsakast af haemophilus influenzae gerð b (hib). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Hexyon Unia Europejska - islandzki - EMA (European Medicines Agency)

hexyon

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - bóluefni - hexyon (dtap-ipv-hb-hib) er ætlað fyrir aðal og orku bólusetningu ungbarna og smábörn frá sex vikna gegn barnaveiki, stífkrampa, stífkrampa, lifrarbólgu b, mænusótt og innrásar sjúkdóma sem orsakast af haemophilus influenzae gerð b (hib). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.